XGN Q4 2025: Pharma Services Backlog Tops $4M, Raising Visibility on Diversification Strategy
XGN’s Q4 2025 call revealed a business in the midst of disciplined reinvestment, with pharma services revenue and backlog marking a meaningful shift in the company’s revenue mix. Despite near-term ASP (average selling price, per-test revenue) pressure, management’s focus on commercial expansion, R&D, and payer engagement signals a push for durable growth and margin recovery. Investors should watch for ASP stabilization and pharma services execution as key levers for profitability inflection in 2027 and beyond.
Summary
- Pharma Services Momentum: Revenue and backlog growth in pharma services highlight a new diversification lever.
- Operational Discipline: Expense growth remains below revenue, with targeted investments in commercial and R&D talent.
- Profitability Path: Break-even targets shift upward, but margin and cash flow inflection remain central priorities.
Performance Analysis
XGN delivered a year of double-digit revenue growth, driven by test volume expansion and the emergence of pharma services as a material contributor. The core autoimmune diagnostics business saw volume growth outpace ASP expansion, with 137,004 advised CTD tests performed in 2025 and ordering physicians rising to 2,690. However, ASP faced a reset in the second half, ending the year at approximately $430 per test, down from prior levels but stabilized sequentially.
Pharma services, XGN’s contract research and biomarker testing for pharmaceutical partners, posted $1.7 million in revenue—up from just $100,000 the prior year—and now boasts a $4 million backlog expected to be realized over two to three years. Gross margin compressed to 58% from 60%, reflecting ASP pressure and incremental costs from new biomarker launches, though COGS (cost of goods sold) per test tracked favorably to internal targets. Operating expenses grew 13%, well below the 20% revenue growth rate, as management prioritized commercial and R&D investment while holding G&A flat.
- Pharma Services Scale-Up: Pharma services now represent a meaningful revenue stream, with robust backlog visibility.
- ASP Reset Managed: In-period ASP stabilized in Q4 after a client bill loss, with management expecting gradual recovery.
- Expense Leverage Emerging: Operating expense growth lagged revenue, signaling early scale benefits.
Adjusted EBITDA loss improved modestly, and XGN exited the year with $32 million in cash and over $43 million in combined cash and receivables, reinforcing runway for continued investment. The company’s 2026 guidance calls for $70–$73 million in revenue, with high single-digit volume and low single-digit ASP growth assumptions.
Executive Commentary
"We're creating a foundation for a meaningful, innovative cadence, evaluating select inorganic opportunities, and prioritizing R&D efforts that can support our intent to own the autoimmune diagnostic space."
John, Chief Executive Officer
"The momentum of our pharma services offering continues to be robust. In 2025, the business generated $1.7 million of revenue, up significantly from roughly $100,000 in 2024. Our efforts here are bearing fruit, now with over $4 million in backlog value that we expect to realize over the next two to three years."
Jeff, Chief Financial Officer
Strategic Positioning
1. Pharma Services Diversification
XGN’s pharma services business, focused on providing biomarker testing and research services to pharmaceutical partners, is gaining traction as a strategic growth vector. The $4 million backlog and rapid revenue ramp signal both validation and future visibility, supporting a more diversified revenue base beyond core diagnostic testing.
2. ASP Optimization and Payer Engagement
Management continues to prioritize average selling price expansion through revenue cycle management, payer negotiations, and advocacy with physician societies. While ASP reset lower after a client bill loss, initiatives such as new biomarker launches and direct engagement with payers and the American College of Rheumatology (ACR) are expected to drive incremental ASP gains in late 2026 and beyond.
3. Commercial Footprint Expansion
XGN expanded sales territories from 40 to 45 in 2025, with a disciplined approach to talent acquisition and training. The company’s salesforce ramp is expected to reach full productivity by mid-2026, supporting both volume growth and deeper account penetration, especially as new biomarkers and clinical indications come online.
4. R&D Pipeline and Innovation Cadence
Seven new biomarkers were launched in 2025, with additional pipeline investments aimed at expanding the clinical utility of XGN’s platform. The company’s myositis product, targeted for 2027, exemplifies a strategy of leveraging internal R&D and targeted inorganic opportunities to own the autoimmune diagnostics niche.
5. Margin Management and Scale Leverage
Despite gross margin compression from ASP and biomarker mix, COGS per test remains favorable, and management expects margin recovery as ASPs rise and scale is achieved. The path to mid-60s gross margin is tied to both pricing initiatives and fixed cost leverage as volumes increase.
Key Considerations
Q4 2025 underscores XGN’s transition from a pure-play diagnostics company to a more diversified platform with embedded pharma services and a growing R&D pipeline. The quarter’s results and commentary highlight several strategic inflection points:
Key Considerations:
- Pharma Services Validation: Backlog growth and revenue ramp provide a new pillar of non-patient revenue and greater predictability.
- ASP Recovery Path: Stabilization after the Northwell client bill loss, with management emphasizing incremental payer wins and advocacy as upside drivers.
- Salesforce Productivity Timing: Recent sales territory expansions are not yet fully reflected in results, with full impact expected by mid-2026.
- R&D as a Differentiator: Pipeline breadth and innovation cadence are increasingly central to the long-term thesis, with myositis and other indications expanding addressable market.
- Profitability Thresholds Shifted: Break-even revenue target increased to $80 million, reflecting deliberate reinvestment, but gross margin tailwinds and cash discipline remain in focus.
Risks
ASP volatility remains a key risk, particularly as commercial payer negotiations and biomarker reimbursement timelines are inherently unpredictable. Gross margin is vulnerable to further ASP pressure or slower-than-expected uptake of new biomarkers. The pharma services backlog provides visibility, but execution risk remains as XGN scales this business. Regulatory developments, especially the timing and scope of local coverage determinations, could materially impact future reimbursement and pipeline monetization.
Forward Outlook
For Q1 2026, XGN guided to:
- Continued high single-digit volume growth
- Low single-digit ASP growth from Q4 2025 levels
For full-year 2026, management guided to:
- Total revenue of $70–$73 million
Management emphasized several drivers for the year:
- Visibility from pharma services backlog realization
- Late-year ASP gains from payer engagement and biomarker traction
- Salesforce ramp and new product launches to drive volume and account penetration
Takeaways
XGN’s Q4 2025 results position the company as a disciplined operator with expanding revenue streams and a maturing commercial platform. While profitability thresholds have shifted upward, the company’s pharma services momentum and R&D cadence provide new levers for long-term value creation.
- Pharma Services as a Growth Engine: Backlog and revenue ramp support a more diversified, resilient business model.
- ASP and Margin Recovery in Focus: Execution on payer engagement and biomarker monetization remains the critical swing factor for margin expansion and cash flow inflection.
- 2026–2027 Inflection Watch: Investors should monitor progress on ASP recovery, pharma services backlog conversion, and myositis product development as key catalysts for re-rating the equity.
Conclusion
XGN’s disciplined reinvestment and diversification into pharma services are reshaping its long-term trajectory. The company’s ability to drive ASP recovery, realize pharma services backlog, and deliver innovation cadence will determine the timing and durability of its path to profitability.
Industry Read-Through
XGN’s pharma services ramp and backlog visibility signal a broader industry trend of diagnostics companies leveraging core laboratory expertise to access adjacent revenue streams from pharma partnerships. The emphasis on payer engagement, advocacy, and R&D-driven test expansion reflects the increasing complexity and opportunity in autoimmune and specialty diagnostics. Competitors with narrow test menus or less diversified revenue models may face greater margin volatility, while those investing in commercial and R&D scale are better positioned to weather reimbursement resets and capitalize on emerging clinical needs. The evolving reimbursement landscape, including the importance of local coverage determinations and advocacy with physician societies, is a sector-wide theme that will shape winners and losers in the next cycle.